PPARG and colitis: Several studies have demonstrated that the in vivo administration of PPARγ ligands inhibited adjuvant-induced arthritis, colitis, and atherosclerosis in animal models [22-24], raising the possibility that PPARγ might be a critical component of the inflammatory process.